学科分类
/ 19
373 个结果
  • 简介:AbstractBackground:Glioblastoma is one of the most common malignant brain tumors. Conventional clinical treatment of glioblastoma is not sufficient, and the molecular mechanism underlying the initiation and development of this disease remains unclear. Our study aimed to explore the expression and function of miR-873a-5p in glioblastoma and related molecular mechanism.Methods:We analyzed the most dysregulated microRNAs from the Gene Expression Omnibus (GEO) database and examined the expression of miR-873-5p in 20 glioblastoma tissues compared with ten normal brain tissues collected in the Zhejiang Tongde Hospital. We then overexpressed or inhibited miR-873-5p expression in U87 glioblastoma cell lines and analyzed the phenotype using the cell counting kit-8 assay, wound healing assay, and apoptosis. In addition, we predicted upstream and downstream genes of miR-873-5p in glioblastoma using bioinformatics analysis and tested our hypothesis in U87 cells using the luciferase reporter gene assay and Western blotting assay. The differences between two groups were analyzed by Student’s t test. The Kruskal-Wallis test was used for the comparison of multiple groups. A P < 0.05 was considered to be significant.Results:The miR-873-5p was downregulated in glioblastoma tissues compared with that in normal brain tissues (normal vs. tumor, 0.762 ± 0.231 vs. 0.378 ± 0.114, t= 4.540, P < 0.01). Overexpression of miR-873-5p inhibited cell growth (t= 6.095, P < 0.01) and migration (t= 3.142, P < 0.01) and promoted cell apoptosis (t= 4.861, P < 0.01), while inhibition of miR-873-5p had the opposite effect. Mechanistically, the long non-coding RNA HOTAIRM1 was found to act as a sponge of miR-873-5p to activate ZEB2 expression in U87 cells.Conclusions:We uncovered a novel HOTAIRM1/miR-873-5p/ZEB2 axis in glioblastoma cells, providing new insight into glioblastoma progression and a theoretical basis for the treatment of glioblastoma.

  • 标签: MicroRNA Long non-coding RNA ZEB2 Glioblastoma
  • 简介:Awhitelong-lastingphosphorCa2MgSi2O7:Dy3+waspreparedbythesolid-statereaction.Astrongbandpeakedat260nmwasshownintheexcitationspectrumof578nmemission,whichmightbeattributedtotheoxygendeficiencyofthehost.Afterirradiatedwith254nmfor4min,thewhiteafterglowofthesamplecouldbeseenfor3h.Moreover,thedepthsandfrequencyfactorsoftrapcenterswerecal-culatedfromthethermo-luminescencecurveofthesample,whichindicatedthatthetrapcenterscorrespondingtothe414Kbandweremorehelpfultothelong-lastingphosphorescence.

  • 标签: WHITE long-lasting phosphor SILICATE DYSPROSIUM THERMO-LUMINESCENCE
  • 简介:AbstractBackground:Cumulative blood pressure (BP), a measure incorporating the level and duration of BP exposure, is associated with the risk of cardiovascular disease (CVD). However, the level at which cumulative BP could significantly increase the risk remains unclear. This study aimed to investigate the association of 15-year cumulative BP levels with the long-term risk of CVD, and to examine whether the association is independent of BP levels at one examination.Methods:Data from a 26-year follow-up of the Chinese Multi-provincial Cohort Study-Beijing Project were analyzed. Cumulative BP levels between 1992 and 2007 were calculated among 2429 participants free of CVD in 2007. Cardiovascular events (including coronary heart disease and stroke) occurring from 2007 to 2018 were registered. Adjusted hazard ratios (HRs) for CVD incidence associated with quartiles of cumulative systolic blood pressure (SBP) and diastolic blood pressure (DBP) were calculated.Results:Of the 2429 participants, 42.9% (1042) were men, and the mean age in 2007 was 62.1 ± 7.9 years. Totally, 207 CVD events occurred during the follow-up from 2007 to 2018. Participants with higher levels of cumulative SBP or DBP exhibited a higher incidence rate of CVD (P < 0.001). Compared with the lowest quartile of cumulative SBP, the HR for CVD was 1.03 (95% confidence interval [CI]: 0.59-1.81), 1.69 (95% CI: 0.99-2.87), and 2.20 (95% CI: 1.21-3.98) for the second to the fourth quartile of cumulative SBP, and 1.46 (95% CI: 0.86-2.48), 1.99 (95% CI: 1.18-3.35), and 2.08 (95% CI: 1.17-3.71) for the second to the fourth quartile of cumulative DBP, respectively. In further cross-combined group analyses with BP measurements in 2007, 15-year cumulative BP levels higher than the median, that is, 1970.8/1239.9 mmHg·year for cumulative SBP/DBP, which were equivalent to maintaining SBP/DBP levels of 131/83 mmHg or above on average in 15 years, were associated with higher risk of CVD in subsequent years independent of BP measurements at one-time point.Conclusion:Cumulative exposure to moderate elevation of BP is independently associated with increased future cardiovascular risk.

  • 标签: Blood pressure Cardiovascular disease Cohort study
  • 简介:AbstractBackground:There is limited information about thymosin α1 (Tα1) as adjuvant immunomodulatory therapy, either used alone or combined with other treatments, in patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the effect of adjuvant Tα1 treatment on long-term survival in margin-free (R0)-resected stage IA-IIIA NSCLC patients.Methods:A total of 5746 patients with pathologic stage IA-IIIA NSCLC who underwent R0 resection were included. The patients were divided into the Tα1 group and the control group according to whether they received Tα1 or not. A propensity score matching (PSM) analysis was performed to reduce bias, resulting in 1027 pairs of patients.Results:After PSM, the baseline clinicopathological characteristics were similar between the two groups. The 5-year disease-free survival (DFS) and overall survival (OS) rates were significantly higher in the Tα1 group compared with the control group. The multivariable analysis showed that Tα1 treatment was independently associated with an improved prognosis. A longer duration of Tα1 treatment was associated with improved OS and DFS. The subgroup analyses showed that Tα1 therapy could improve the DFS and/or OS in all subgroups of age, sex, Charlson Comorbidity Index (CCI), smoking status, and pathological tumor-node-metastasis (TNM) stage, especially for patients with non-squamous cell NSCLC and without targeted therapy.Conclusion:Tα1 as adjuvant immunomodulatory therapy can significantly improve DFS and OS in patients with NSCLC after R0 resection, except for patients with squamous cell carcinoma and those receiving targeted therapy. The duration of Tα1 treatment is recommended to be >24 months.

  • 标签: Non-small cell lung cancer Resection Adjuvant therapy Thymosin α1
  • 简介:作为报导Y2O2S的改进:Tb3+,白光的长持续的黄磷:Y2O2S:Tb3+,Sm3+被准备由固态反应。光致发光系列证明在紫外刺激下面的Tb3+和Sm3+排出物的位置和形状在这位主人是类似的,它在不同刺激下面保证了一种稳定的白排放颜色(IEC的日光标准)。共同做的样品的腐烂曲线显示二个离子的排出物的腐烂时间是靠近的。热照明测量建议做的Sm3+离子创造的陷井是有用的推迟共同做的样品的白晚霞。因此,共同做的Sm3+离子的功能作为改进样品的白排放颜色并且充当新陷井中心被证实。

  • 标签: 白色 无机发光材料 稀土
  • 作者: 王林 段晋涛 孟祥欣 宋文龙
  • 学科:
  • 创建时间:2023-10-16
  • 机构:中航西安飞机工业集团股份有限公司  陕西 西安  710000
  • 简介:【摘要】:某工业(集团)有限公司670号机棚项目采用双曲线倒三角管桁架结构,轴线尺寸为138m×51m,跨度69m,安装高度为15m,弧形最高点为21.5m,弧形高度为6.5m,考虑到桁架拼装及吊装思路及方案的选择,本文阐述了地面拼装法及空中吊装法等施工关键技术,结合数值模拟结果,指导现场施工,最终施工效率比常规施工提升一倍,质量优,经济效益好,安全环保性高。

  • 标签: 双曲线倒三角管桁架 机棚 侧躺 拼装 数值模拟
  • 简介:AbstractBackground:Pancreatic cancer (PC) is a highly deadly malignancy with few effective therapies. We aimed to unmask the role that long non-coding RNA small nucleolar RNA host gene 6 (SNHG6) plays in PC cells by targeting far upstream element binding protein 1 (FUBP1) via microRNA-26a-5p (miR-26a-5p).Methods:SNHG6 expression was predicted by bioinformatics, followed by verification via reverse transcription quantitative polymerase chain reaction. Then, the interactions among SNHG6, miR-26a-5p, and FUBP1 were detected through online software analysis, dual luciferase reporter assay and RNA pull-down. After that, cells were treated with different small interfering RNAs and/or mimic to determine the interactions among SNHG6, miR-26a-5p, and FUBP1 and their roles in PC cells. Finally, the role of SNHG6 in tumor growth in vivo was evaluated by measuring the growth and weight of transplanted tumors in nude mice. A t-test, one-way and two-way analysis of variance were used for data analysis.Results:Compared with that in normal tissues, SNHG6 was highly expressed in PC tissues (1.00 ± 0.05 vs. 1.56 ± 0.06, t= 16.03, P < 0.001). Compared with that in human pancreatic duct epithelial cells (HPDE6-C7), SNHG6 showed the highest expression in PANC-1 cells (1.00 ± 0.06 vs. 3.87 ± 0.13, t= 34.72, P < 0.001) and the lowest expression in human pancreatic cancer cells (MIAPaCa-2) (1.00 ± 0.06 vs. 1.41 ± 0.07, t= 7.70, P= 0.0015). Compared with the levels in the si-negative control group, SNHG6 (0.97 ± 0.05 vs. 0.21 ± 0.06, t = 16.85, P < 0.001), N-cadherin (0.74 ± 0.05 vs. 0.41 ± 0.04, t= 8.93, P < 0.001), Vimentin (0.55 ± 0.04 vs. 0.25 ± 0.03, t= 10.39, P < 0.001), and β-catenin (0.62 ± 0.05 vs . 0.32 ± 0.03, t= 8.91, P < 0.001) were decreased, while E-cadherin (0.65 ± 0.06 vs. 1.36 ± 0.07, t= 13.34, P < 0.001) was increased after SNHG6 knockdown or miR-26a-5p overexpression, accompanied by inhibited cell proliferation, migration, and invasion. SNHG6 overexpression exerted the opposite effects. SNHG6 upregulated FUBP1 expression by sponging miR-26a-5p. Silencing SNHG6 blocked the growth of PC in vivo.Conclusion:Silencing SNHG6 might ameliorate PC through inhibition of FUBP1 by sponging miR-26a-5p, thus providing further supporting evidence for its use in PC treatment.

  • 标签: Prostatic neoplasms Long non-coding RNA SNHG6 microRNA-26a FUBP1 Proliferation Invasion Migration Apoptosis
  • 简介:AbstractBackground:Long non-coding RNAs (lncRNAs) play key roles in human cancers. In our previous study, we demonstrated that lncRNA FKBP prolyl isomerase 9 pseudogene 1 (FKBP9P1) was highly expressed in head and neck squamous cell cancer (HNSCC) tissues. However, its functional significance remains poorly understood. In the present study, we identify the role and potential molecular biologic mechanisms of FKBP9P1 in HNSCC.Methods:Quantitative real-time polymerase chain reaction was used to detect the expression of FKBP9P1 in HNSCC tissues, matched adjacent normal tissues, human HNSCC cells (FaDu, Cal-27, SCC4, and SCC9), and human immortalized keratinocytes cell HaCaT (normal control). Cal-27 and SCC9 cells were transfected with sh-FKBP9P1-1, sh-FKBP9P1-2, and normal control (sh-NC) lentivirus. Cell counting kit-8 assay, colony formation assay, wound healing assay, and trans-well assay were used to explore the biologic function of FKBP9P1 in HNSCC cells. Furthermore, western blotting was used to determine the mechanism of FKBP9P1 in HNSCC progression. Chi-squared test was performed to assess the clinical significance among FKBP9P1 high-expression and low-expression groups. Survival analyses were performed using the Kaplan-Meier method and assessed using the log-rank test. The comparison between two groups was analyzed by Student t test, and comparisons among multiple samples were performed by one-way analysis of variance and a Bonferroni post hoc test.Results:FKBP9P1 expression was significantly up-regulated in HNSCC tissues (tumor vs. normal, 1.914 vs. 0.957, t = 7.746, P < 0.001) and cell lines (P < 0.01 in all HNSCC cell lines). Besides, the median FKBP9P1 expression of HNSCC tissues (1.677) was considered as the threshold. High FKBP9P1 level was correlated with advanced T stage (P = 0.022), advanced N stage (P = 0.036), advanced clinical stage (P = 0.018), and poor prognosis of HNSCC patients (overall survival, P = 0.002 and disease-free survival, P < 0.001). Knockdown of FKBP9P1 led to marked repression in proliferation, migration, and invasion of HNSCC cells in vitro (P all < 0.01). Mechanistically, silencing FKBP9P1 was observed to restrain the PI3K/AKT signaling pathway.Conclusions:Silencing lncRNA FKBP9P1 represses HNSCC progression and inhibits PI3K/AKT (phosphatidylinositol 3 kinase/AKT Serine/Threonine Kinase) signaling in vitro. Therefore, FKBP9P1 could be a potential new target for the diagnosis and treatment of HNSCC patients.

  • 标签: Head and neck squamous cell carcinoma Long non-coding RNA FKBP prolyl isomerase 9 pseudogene 1 PI3K/AKT signaling pathway
  • 简介:AbstractBackground:Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.Methods:We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on the World Health Organization (WHO)-recommended first-line treatment for >6 months with a plasma viral load >1000 copies/mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%.Results:At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% of patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL, meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated. The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration. Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group.Conclusions:The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.Trial registration:ClinicalTrials.gov Identifier: NCT02369965; https://www.clinicaltrials.gov.Chinese Clinical Trial Registry No. ChiCTR-TRC-14004276; http://www.chictr.org.cn/enindex.aspx

  • 标签: HIV Fusion inhibitor Albuvirtide LPV/r Phase 3 clinical trial
  • 作者: 熊长春 顾冰雪
  • 学科:
  • 创建时间:2023-10-27
  • 机构:(葛洲坝集团四川内遂高速公路有限公司  四川 遂宁  629000)
  • 简介:摘要:共青团作为党的后备军,承担着组织联系青年、培养青年、发现人才、储备人才的重要使命。针对目前企业对共青团建设重视程度不高、职能弱化的现状,各企业要结合行业特色,充分发挥党组织的政治优势、组织优势和思想引领优势,激发青年立足岗位的创新创效动力,引领青年团队积极探索、促进青年成才、行业管理规范化、推动提升行业文明程度。葛洲坝集团四川内遂高速公路有限公司目前是高速公路工程项目运营单位,在以“党建带团建”的实践探索中,历经公司多年的发展创新,总结归纳出了一套行之有效的管理办法,探索出了一条可持续发展的模式。

  • 标签: 高速运营 党建带团建 持续发展 创新机制
  • 简介:在激进的前列腺切除术(RP)或外部横梁放射治疗(EBRT)以后的健康相关的quality-of-life(HRQOL)没在与疾病风险层化的关系与oncological结果一起被学习。而且,这些治疗途径的长期的结果没被学习。我们回顾地分析了在收到RP的连续病人之间的oncological结果(n=86)并且EBRT(n=76)为局部性的前列腺癌症。HRQOL和功能的结果能在62RP(79%)和54EBRT(79%)被估计在一个3年的后续时期上的病人(中部:41个月)用医药结果学习,短Form-36(SF-36)和加利福尼亚大学洛杉机前列腺癌症索引(UCLA一种总线标准)。5年的生物化学的没有前进的幸存没在RP和EBRT组之间不同为低风险(74.6%对75.0%,P=0.931)并且中间风险(61.3%对71.1%,P=0.691)病人。为高风险的病人,没有前进的幸存比在EBRT组(79.7%)在RP组(45.1%)是更低的(P=0.002)。一般HRQOL在二个组之间是可比较的。关于功能的结果,RP组比EBRT组在尿功能和不太尿的麻烦和性麻烦上报导了更低的分数(P<0.001,P<0.05并且P<0.001,分别地)。与风险层化,在RP组的低风险、中间风险的病人在EBRT组比病人报导了更差的尿功能(P<0.001为各个)。在EBRT组的高风险的病人的性功能比一样的风险RP病人的好(P<0.001)。生物化学的复发没在任何一个组与UCLA一种总线标准分数被联系。在结论,低--可以在长期的后续期间向与RP对待的中间风险的病人汇报相对减少的尿功能。病人在治疗以后的HRQOL没取决于生物化学的复发。

  • 标签: 健康相关生活质量 前列腺癌根治术 体外放射治疗 危险分层 肿瘤患者 病患结果
  • 简介:AbstractBackground:Myocardial infarction occurs due to insufficient (ischemia) blood supply to heart for long time; plasmacytoma variant translocation 1 (PVT1) is a long non-coding RNAs (lncRNAs) involved in the pathogenesis of various diseases, including heart disease; However, few studies have explored its role. The present study evaluated the effects of lncRNA PVT1 on hypoxic rat H9c2 cells.Methods:Hypoxic injury was examined by measuring cell viability and apoptosis by using cell counting kit-8 activity and flow cytometry assays. Gene expressions after hypoxia were estimated by quantitative real time polymerase chain reaction and the signaling pathway were explored by Western blot analysis. RNA immunoprecipitation and luciferase reporter assays were applied to examine the interactions among genes. Data were analyzed using t-test with one-way or two-way analysis of variance.Results:The lncRNA PVT1 is up-regulated in hypoxia-stressed H9c2 cells and knockdown of PVT1 mitigates hypoxia-induced injury in H9c2 cells. PVT1 acts as a sponge for miR-135a-5p and knockdown of PVT1 attenuated the increased hypoxia-induced injury by up-regulating miR-135a-5p. Forkhead box O1 (FOXO1) was identified as a target of miR-135a-5p, and the expression was negatively regulated by miR-135a-5p. The exploration of the underlying mechanism demonstrated that knockdown of FOXO1 reversed PVT1/miR-135a-5p mediated hypoxia-induced injury in H9c2 cells.Conclusions:PVT1 plays a crucial role in hypoxia-injured H9c2 cells through sponging miR-135a-5p and then positively regulating FOXO1.

  • 标签: Acute myocardial infarction PVT1 miR-135a-5p FOXO1